张育泉,程义局,杜娟,李瑞雪,潘琳,杨文婷,吴潇,卢琴,李向魁
ZHANG Yuquan,CHENG Yiju,DU Juan,LI Ruixue,PAN Lin,YANG Wenting,WU Xiao,LU Qin,LI Xiangkui

• 1:贵州医科大学附属医院呼吸与危重症医学科
• 2:贵阳市公共卫生救治中心呼吸与危重症医学科
• 3:贵州医科大学研究生院

摘要(Abstract)：

目的 探讨NOD样受体热蛋白结构域相关蛋白3信使RNA(NLRP3 mRNA)、核因子激活的B细胞的κ-轻链增强(NF-κB)、降钙素原(PCT)与慢性阻塞性肺疾病(COPD)患者肺功能及肺动脉高压的关系。方法 选取COPD稳定期患者47例、COPD急性加重期(AECOPD)未合并肺动脉高压患者47例及AECOPD合并肺动脉高压患者47例，以同期体检健康人群为对照组(n=47),抽取4组受检者空腹静脉血，采用酶联免疫吸附法检测血液NF-κB和PCT表达，采用聚合酶链式反应(PCR)法检测外周血淋巴细胞NLRP3 mRNA的表达；采用肺功能仪检测对照组、COPD稳定期组及AECOPD未合并肺动脉高压组受检者的肺功能指标[第一秒用力呼气容积(FEV_(1 ))、用力肺活量(FVC)、FEV1/FVC、FEV_1占预计值的百分比(FEV_1%pred)];采用超声心动仪测量AECOPD未合并肺动脉高压组和AECOPD合并肺动脉高压组受检者的肺动脉高压、右心房径及右心室径。结果 受检者外周血PCT、NLRP3 mRNA、NF-κB水平表现为AECOPD未合并肺动脉高压组>COPD稳定期组>对照组(P<0.05);AECOPD未合并肺动脉高压组患者血清NLRP3 mRNA、PCT、NF-κB表达水平较AECOPD合并肺动脉高压组减少(P<0.05);受检者PCT、NLRP3 mRNA、NF-κB与肺功能FEV_1%pred、FEV_1/FVC指标呈负相关(P<0.05),与肺动脉高压、右心房内径、右心室内径3个指标均呈正相关(P<0.05)。结论 外周血NLRP3 mRNA、NF-κB、PCT水平可作为COPD疾病的监测指标。
Objective To investigate the relationship between NOD-like receptor thermoprotein domain-related protein 3 messenger RNA(NLRP3 mRNA), nuclear factor-activated κ-light chain enhancement(NF-κB), procalcitonin(PCT), and pulmonary function and hypertension in patients with chronic obstructive pulmonary disease(COPD). Methods Patients with stable COPD, acute exacerbation of COPD(AECOPD) without pulmonary hypertension and AECOPD with pulmonary hypertension were selected as stable COPD group(n=47), AECOPD without pulmonary hypertension group(n=47), AECOPD with pulmonary hypertension group(n=47), and the healthy people in the same period as the control group(n=47). Fasting venous blood was collected from the four groups, and the expressions of serum NF-κB and PCT were detected by enzyme-linked immunosorbent assay. The expression of NLRP3 mRNA in peripheral blood lymphocytes was detected by polymerase chain reaction(PCR). The pulmonary function indexes(forced expiratory volume in one second(FEV_1), forced vital capacity(FVC), FEV_1/FVC, and the percentage of FEV_1 to predicted value(FEV_1%PRED) in the control group, stable COPD group and AECOPD without pulmonary hypertension group were detected by pulmonary function instrument. Pulmonary hypertension, right atrial diameter, and right ventricular diameter were measured by echocardiography in AECOPD group without pulmonary hypertension and AECOPD group with pulmonary hypertension. Results The levels of PCT, NLRP3 mRNA, and NF-κB in AECOPD patients without pulmonary hypertension group were higher than those in stable COPD group and the control group(P<0.05). The expression levels of NLRP3 mRNA, PCT and NF-κB in the AECOPD without pulmonary hypertension group were significantly lower than those in the AECOPD with pulmonary hypertension group(P<0.05). PCT, NLRP3 mRNA, and NF-κB were negatively correlated with FEV_1%PRED and FEV_1/FVC(P<0.05), and positively correlated with pulmonary hypertension, right atrial diameter, and right ventricular diameter(P<0.05). Conclusion NLRP3 mRNA, NF-κB, and PCT can be used as monitoring indexes of COPD.

关键词(KeyWords)： 阻塞性肺病,慢性;NOD样受体热蛋白结构域相关蛋白3信使RNA;核因子激活的B细胞的κ-轻链增强;降钙素原;肺功能;肺动脉高压
chronic obstructive pulmonary disease;nod-like receptor thermoprotein domain associated protein 3 messenger RNA;nuclear factor-kappaB;procalcitonin;lung function;pulmonary hypertension

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金地区项目(81760016);; 贵州省科技厅基金项目(黔科合基础-ZK一般347[202142920285210617])

作者(Author): 张育泉,程义局,杜娟,李瑞雪,潘琳,杨文婷,吴潇,卢琴,李向魁
ZHANG Yuquan,CHENG Yiju,DU Juan,LI Ruixue,PAN Lin,YANG Wenting,WU Xiao,LU Qin,LI Xiangkui

DOI: 10.19367/j.cnki.2096-8388.2023.06.012

参考文献(References)：

• [1] VASILESCU D M,MARTINEZ F J,MARCHETTI N,et al.Noninvasive imaging biomarker identifies small airway damage in severe chronic obstructive pulmonary disease[J] .American Journal of Respiratory and Critical Care Medicine ,2019,200(5):575-581.
• [2] SINGANAYAGAM A,GLANVILLE N,CUTHBERTSON L.Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease[J].Science Translational Medicine,2019,11:507.
• [3] ROMEM A,ROKACH A,BOHADANA A,et al.Identification of asthma-COPD overlap,asthma,and chronic obstructive pulmonary disease phenotypes in patients with airway obstruction:influence on treatment approach[J].Respiration,2020,99(1):35-42.
• [4] RAGLAND M F,BENWAY C J,LUTZ S M,et al.Genetic advances in chronic obstructive pulmonary disease insights from COPD gene [J].American Journal of Respiratory and Critical Care Medicine,2019,200(6):677-690.
• [5] CHAN S M H,SELEMIDIS S,BOZINOVSKI S,et al.Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD):clinical significance and therapeutic strategies[J].Pharmacology & Therapeutics ,2019,198 :160-188.
• [6] LI L,NAN N Z,XIANG Y M,et al.Personalized variable vs fixed-dose systemic corticosteroid therapy in hospitalized patients with acute exacerbations of COPD:a prospective,multicenter,randomized,open-Label clinical trial[J].Chest,2021,160(5):1660-1669.
• [7] CHOI J,OH J Y,LEE Y S,et al.The association between blood eosinophil percent and bacterial infection in acute exacerbation of chronic obstructive pulmonary disease[J].International Journal of Chronic Obstructive Pulmonary Disease ,2019,14:953-959.
• [8] KIM R Y,SUNKARA K P,BRACKE K R,et al.A microRNA-21 mediated SATB1/S100A9/NF-κB axis promotes chronic obstructive pulmonary disease pathogenesis[J].Science Translational Medicine,2021 ,13(621):7223.
• [9] HUANG L X,WANG J X,GU X Y,et al.Procalcitonin-guided initiation of antibiotics in AECOPD inpatients:study protocol for a multicenter randomised controlled trial[J].British Medicine Open,2021,11(8):e049515.
• [10]PASCOE S,BARNES N,BRUSSELLE G,et al.Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease:analysis of the IMPACT trial[J].Lancet Respiratory Medicine,2019(9):745-756.
• [11]KLINGER1 Z G S V J R.Guidelines for the treatment of pulmonary arterial hypertension[J].Lung,2020,198(4):581-596.
• [12]张胜睿，杨栋梁，匡智明，等.重症慢性阻塞性肺疾病急性发作期患者血清D-二聚体、超敏C反应蛋白及降钙素原表达及其临床意义[J].中国老年学杂志，2019,39(5):1084-1086.
• [13]LI Y ,MIN L F,ZHANG X.Usefulness of procalcitonin (PCT),C-reactive protein (CRP),and white blood cell (WBC) levels in the differential diagnosis of acute bacterial,viral,and mycoplasmal respiratory tract infections in children[J].British Medical Council Pulmonary Medicine,2021,21:386.
• [14]CABRAL L,FERNANDES M,MARQUES S.PCT Kinetics in the first week postburn for sepsis diagnosis and death prognosis-an accuracy study[J].Journal of Burn Care & Research,2021,42(3):545-554.
• [15]STELLARI F F,SALA A,RUSCITTI F,et al.CHF6001 inhibits NF-kappaB activation and neutrophilic recruitment in LPS-induced lung inflammation in mice [J].Front Pharmacol,2019,10:1337.
• [16]LI J,QIU C,XU P,et al.Casticin improves respiratory dysfunction and attenuates oxidative stress and inflammation via inhibition of NF-κB in a chronic obstructive pulmonary disease model of chronic cigarette smoke-exposed rats [J].Drug Design,Development and Therapy,2020,14:5019-5027.
• [17]UYSAL P,SIMSEK G,DURMUS S,et al.Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease [J].International Journal of Chronic Obstructive Pulmonary Disease,2019,14:321-330.
• [18]ZHANG X L,WANG Y P,HE X,et al.Diagnosis of chronic obstructive pulmonary disease and regulatory mechanism of miR-149-3p on alveolar inflammatory factors and expression of surfactant proteins A (SP-A) and D (SP-D) on lung surface mediated by Wnt pathway[J].Computational Intelligence and Neuroscience,2022,2022:7205016.
• [19]RIGAUTS C,AIZAWA J,TAYLOR S,et al.Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease[J].European Respiratory Journal,2022 ,59(5):2101293.
• [20]MO R,ZHANG J,CHEN Y,et al.Nicotine promotes chronic obstructive pulmonary disease via inducing pyroptosis activation in bronchial epithelial cells [J].Molecular Medicine Reports,2022,25(3):92.
• [21]ZHANG J,XU Q,SUN W,et al.New insights into the role of NLRP3 inflammasome in pathogenesis and treatment of chronic obstructive pulmonary disease [J].Journal of Inflammation Research,2021,14:4155-4168.
• [22]CHONG W C,SHASTRI M D,PETERSON G M,et al.The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome:a potential therapeutic target for inflammatory disorders [J].Clinical & Translational Immunology,2021,10(2):e1247.
• [23]贾钦尧，陈绍平，宋珊，等.NLRP3基因多态性与慢性阻塞性肺疾病的相关性[J].中国老年学杂志，2021,41(5):975-978.
• [24]NACHMIAS N,LANGIER S,BRZEZINSKI R Y,et al.NLRP3 inflammasome activity is upregulated in an in-vitro model of COPD exacerbation [J].PLoS One,2019,14(5):e0214622.
• [25]WANG L,CHEN Q,YU Q,et al.TREM1 aggravates chronic obstructive pulmonary disease development via activation NLRP3 inflammasomemediated pyroptosis [J].Inflammation Research 2021,70(9):971-980.

文章评论(Comment)：